European Gram Negative AntiBacterial Engine
ENABLE
ENABLE
News
To receive our quarterly newsletter and learn more on ENABLE project and its achievements,
please send an email to Lilian Löwenau and Clément Robijns at info@nd4bb-enable.eu
Your e-mail address will be used solely for the
purposes of sending out our newsletter. You will be able to
unsubscribe at any time and thereby revoke your consent to receive
the newsletter.
2018
ENABLE Video
published
November 6, 2018
The video
introduces ENABLE, its drug discovery platform, expert network and
explains how to submit an Expression of Interest (EoI).
You can
watch the video on
Youtube.
Coordinated Press
Release: Tackling Antimicrobial Resistance: ENABLE Selects
First Clinical
Candidate
October 16,
2018
Apramycin has been selected as clinical
candidate for the treatment of critical systemic infections caused
by Gram-negative bacteria. You can download the Juvabis Press
Release in the section below.
ENABLE
at the 11th Berlin Conference on Life
Sciences
February 28,
2018
The Berlin
Conference on “Novel Antimicrobials and AMR Diagnostics” took place
on March 2nd, 2018 in the Fraunhofer-Forum in Berlin. The
conference brought together more than 200 people from science and
business, investors and policy makers, startups and health
economists to highlight the most promising technologies, to
showcase best-practice examples and discuss successful business
strategies in the AMR market. Together with the European Investment
Bank, CARB-X and GARDP, ENABLE contributed to the program and took
part in the interactive market place – a session on financing and
funding opportunities for SMEs active in the AMR
field.
2017
Press Release published
December 19,
2017
Please find the
ENABLE Press Release in the section
below.
ENABLE in Nordic Life
Science
Magazine
November 4,
2017
Report about ENABLE in the
Nordic Life Science Magazine
Health Check
Survey
October 9,
2017
ENABLE partners were asked in a Health Check Survey how satisfied they are within the ENABLE project. In a slide deck (please scroll to the bottom of this page for download) ,we have summed up the feedback and suggested improvements.
New IMI Video
#CarryTheTorch
June
30, 2017
"Infections we treated for decades can once again kill". IMI launched a new video on medical research today: #CarryTheTorch
connects the scientific giants of the past to the important work being carried out today.
Watch the movie on youtube: https://youtu.be/cCY0LPr9aLU
ENABLE releases
its third external newsletter
May 22, 2017
We are pleased to present our four new partners and give an update on the reviews that took place within the consortium.
Please find this new issue below.
To suscribe and receive them directly, please send us an email via info@nd4bb-enable.eu
ENABLE at
ECCMID
April 24, 2017
Meet us at the poster presentation corner and get to know the ENABLE project!
You can also have a look at the poster we are presenting here.
Open Call for expertise and capabilities in non-clinical development
February 15, 2017
Thanks to all applicants! We will come back to you shortly.
ENABLE goes live on Twitter
January 27, 2017
To stay updated about the project and related fields, follow us on Twitter.
To contribute and help us become a trend, use #ENABLE
Have a look at our Twitter account
ENABLE released its second external newsletter
January 24th, 2017
This new issue presents ENABLE achievements during Q4 2016.
We also took the opportunity to present our partner Nosopharm and a joint initiative from the ND4BB program: DRIVE-AB.
Please find the second issue of our Newsletter in the section below.
To suscribe to our newsletter and receive them directly, please contact Dr Nathalia Murillo: info@nd4bb-enable.eu
2016
ENABLE consortium
co-organized the Frontiers in Antibiotic Drug Discovery (FiADD) in
Stockholm
September 12-13, 2016
Together with the Swedish Pharmaceutical Society, ENABLE co-organized a two-day conference to showcase future opportunities for antibacterial drug research.
Please about this conference in our 2nd Newsletter, in the section below.
To suscribe to our
newsletter and receive them directly, please contact Dr Nathalia
Murillo: info@nd4bb-enable.eu
ENABLE held its third Annual Meeting in Stockholm
September 12-13, 2016
77 representatives from ENABLE partners gathered in the Royal Coin Cabinett to listen to the latest advances of ENABLE programmes.
Please find full report by clicking here
ENABLE held a workshop on antimicrobial resistance during the BIO Convention
June 6, 2016
We were pleased to welcome more than 100 delegates during this workshop.
Ten companies presented their novel antibiotics and AMR innovation.
Congratulations to Bioversys and Episiome who respectively won the Expert Pannel Best Presentation Award and the Audience Best Presentation Award!
Please find full report and slide by clicking here.
2015
ENABLE introduces a rolling deadline for expressions of interest submitted to the project
October 1st, 2015
From October 1 2015, potential programmes for inclusion in ENABLE can submit an expression of interest (EoI) at any time for assessment and development for full review by the ENABLE Portfolio Management Committee.
For full details about the Open Call Process,
please visit the Join Us ! page
ENABLE holds its first annual meeting in Copenhagen
May 26-27,
2015
Bringing together 80 members of the project from 32 partners, the 3-day meeting heard from all the active programmes in ENABLE together with programme development meetings, expert external speakers and alignment of the project within the wider ND4BB family of projects.
The Research Network joins the ENABLE programme
March
2015
We are pleased to welcome this UK-based research center into our consortium.
It brings to our portfolio a novel gram negative programme, developed through previous international academic research.
2014
ENABLE is officially launched !
April 10th 2014
Our managing entity, University of Uppsala, welcomed the whole consortium for two days in order to officially launch the ENABLE initiative.
2019
ENABLE joins the AMR Challenge
January 2019
The AMR Challenge is a way for governments, private industries, and non-governmental organizations worldwide to make formal commitments that further the progress against antimicrobial resistance. ENABLE's commitment has been published here.
ENABLE at
the
12th Berlin
Conference on Life
Sciences
14 - 15 March, 2019
The Novel Antimicrobials and AMR Diagnostics 2019
conference is a platform for SMEs, start-ups, big pharma, academia,
investors and public institutions to discuss strategies and the
specific challenges faced by SMEs in bringing new antimicrobial
treatments and diagnostics to the market.
ENABLE
representatives will join to the conference as
speakers.
Information about ENABLE
no-cost
extension
6th ENABLE Annual Meeting
held in
Warsaw
24 - 25 September
2019
From 24-25 September 2019, this year’s ENABLE Annual Meeting took place in Warsaw, Poland. The meeting achieved an all-time high attendance record with over 90 attendees. The public-private partnership initiative with partners from EFPIA companies, SMEs, academia and independent experts met to discuss the progress of the quickly developing programmes. As ENABLE is coming to an end in 2021 including the one-year extension, the meeting presented the last opportunity for new teams to enter the initiative.
At this time, the ENABLE project has received 110 Expressions of Interest. Around half of these applications were able to present in front of the expert body of ENABLE, the Portfolio Management Committee. Again, around half of the Expressions of Interest were approved and received funding from ENABLE resources. Currently, the engine progresses eight programmes.
Article on ENABLE published:
Scientists aim for new weapons in fight against
superbugs
14 October
2019
"New weapons are needed to fight drug-resistant
bacteria, one of the biggest threats to global health. By working
on new antibiotics or finding ways to revive existing ones in our
medical arsenal, scientists aim to avoid a return to a world where
even everyday infections may mean death." Anders Karlén and
Diarmaid Hughes gave an interview to the HORIZON EU Research &
Innovation Magazine. You can read the article
here.
Two ENABLE Press
Releases published
18 November
2019
A
Press Release on the candidate selection of Mutabilis and the entry
into Phase I by Juvabis. Both press releases can be downloaded
here.
2021
Mutabilis' EBL-1463 programme: A successful case study from ENABLE
May 2021
The press release can be downloaded here.
Health Check Survey
Press
Release
Tel: 0049 (0)30-264 921-58
Tel: 0049 (0)30-264 921-58
Email: info@nd4bb-enable.eu
The research leading to these results has received support from the Innovative Medicine Initiative Joint Undertaking under grant agreement no 115583, resources of which are composed of financial contributions from the European Union`s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies` in kind contribution.